Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

C3250000

Cyclophosphamid

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Cyclophosphamid Monohydrat, 2-[Bis-(2-chlorethyl)-amino]-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxid, Cytoxan

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C7H15Cl2N2O2P · H2O
CAS-Nummer:
6055-19-2
Molekulargewicht:
279.10
Beilstein:
4678992
MDL-Nummer:
MFCD00149395
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329775031
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

cyclophosphamide

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

49-51 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

[H]O[H].ClCCN(CCCl)P1(=O)NCCCO1

InChI

1S/C7H15Cl2N2O2P.H2O/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14;/h1-7H2,(H,10,12);1H2

InChIKey

PWOQRKCAHTVFLB-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Cyclophosphamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Cyclophosphamid ist ein Stickstofflostderivat, das in der Krebstherapie verbreitete Anwendung findet. Es führt zur Quervernetzung der DNA sowie zum Abbruch von Strängen und induziert Mutationen. Seine klinische Aktivität wird mit einer Abnahme der ALDH1-Aktivität (Aldehyd-Dehydrogenase 1) assoziiert.

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Sales restrictions may apply.

Piktogramme

Skull and crossbonesHealth hazard
GHS06,GHS08

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Oral - Carc. 1B - Muta. 1B - Repr. 1A

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

Ifosfamid European Pharmacopoeia (EP) Reference Standard

I0060000

Ifosfamid

Oxaliplatin United States Pharmacopeia (USP) Reference Standard

USP

1481204

Oxaliplatin

Vincristin -sulfat meets USP testing specifications

Sigma-Aldrich

V8388

Vincristin -sulfat

Kortison-Acetat British Pharmacopoeia (BP) Reference Standard

BP585

Kortison-Acetat

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Doxorubicin -hydrochlorid 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicin -hydrochlorid

Gang Chen et al.
Cancer immunology research, 2(10), 949-961 (2014-08-15)
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines are bioactive, but limited by disease burden and immune tolerance. Cyclophosphamide augments vaccine activity in tolerant neu mice and in patients with metastatic breast cancer. HER2-specific monoclonal antibodies (mAb) enhance vaccine activity in neu
Shivaani Kummar et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(7), 1574-1582 (2015-01-16)
Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative contribution of PARP inhibition to the observed clinical activity, we conducted a randomized
Tanja Wenzler et al.
Antimicrobial agents and chemotherapy, 58(8), 4452-4463 (2014-05-29)
African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine
Sebastian Unizony et al.
Arthritis & rheumatology (Hoboken, N.J.), 67(2), 535-544 (2014-10-22)
CD5+ B cells have been conceptualized as a possible surrogate for Breg cells. The aim of the present study was to determine the utility of CD5+ B cells as biomarkers in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). The absolute and relative
Bridget P Keenan et al.
Gastroenterology, 146(7), 1784-1794 (2014-03-13)
Premalignant lesions and early stage tumors contain immunosuppressive microenvironments that create barriers for cancer vaccines. Kras(G12D/+);Trp53(R172H/+);Pdx-1-Cre (KPC) mice, which express an activated form of Kras in pancreatic tissues, develop pancreatic intraepithelial neoplasms (PanIN) that progress to pancreatic ductal adenocarcinoma (PDA).
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.